A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Clinical trial NCT06186076 · TERMINATED

Trial details

NCT number: NCT06186076
Sponsor: Therapex Co., Ltd
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung EGFR Mutant Advanced Non-Small Cell Lung Cancer

Start date: 2024-06-14
Primary completion: 2025-12-03
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.